Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.

Manuel R Espinoza-Gutarra¹, Brooke A Jarrett², Xiaoliang Wang², Anosheh Afghahi^2,3, Sejong Bae^4,5

¹Department of Medicine, O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL, USA.

²Flatiron Health, New York, NY, USA.

³Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

⁴Department of Biostatistics, Data Science and Epidemiology, Augusta University School of Public Health, Augusta, GA, USA.

⁵Department of Biostatistics, Data Science and Epidemiology, Georgia Cancer Center, Augusta, GA, USA.

PubMed PMC DOI PDF

Abstract

Acute Myeloid Leukemia (AML) is a common hematologic neoplasm in adults and usually carries a grim prognosis. Therapy has traditionally consisted of intensive chemotherapy; however, recent advances have led to the development of Tyrosine Kinase Inhibitors (TKI) as Targeted Therapies for subtypes carrying certain mutations. While the clinical impact of these therapies has been well described, there…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.